![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.135 | -2.91% | 4.51 | 4.41 | 4.99 | 4.53 | 4.51 | 4.53 | 189,892 | 11:53:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/7/2020 08:59 | Fincapp reiterate their £3.60 target, however they emphasise there is significant upside depending on regulatory discussions... talk of a sales pipeline valued at £2-3b as governments stockpile... Personally I’d much rather my elderly relatives took this than a rushed through vaccine with questionable safety implications... Anyone else feel the same? | ![]() 74tom | |
20/7/2020 08:56 | Interested to see how Syn price this now. Remdesivir charge approx $3000 for a 5 oourse treatment plan. No need to Syn to undercut the market leader, so let us assume $600 per vial for Syn. Multiply that by the number of doses required per patient and what numbers do we get? Also, how quickly can Syn ramp up production? | ![]() mdchand | |
20/7/2020 08:54 | I bought some today. Seems strange to buy a share that has just gone up 180% but good news is good news and can’t be ignored | mikro1 | |
20/7/2020 08:52 | This should continue up trend thru Tuesday as well. BBC reporter was clearly broadcasting from premier inn hotel Southampton, so probably be more coverage on the telly after press conference- this evening and tomorrow's breakfast news. Also rag tops will pick this up and we'll see write up tomorrow. My plan is to top slice late Tuesday or Early Wednesday. As by then I think we'll be over bought by then | ![]() paraguay | |
20/7/2020 08:52 | The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it.The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection. The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.Patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, Synairgen claims.It said the trial also indicated "very significant" reductions in breathlessness among patients who received the treatment.In addition, the average time patients spent in hospital is said to have been reduced by a third, for those receiving the new drug - down from an average of nine days to six days.? UK hospital trials new coronavirus treatment drug? Life-saving coronavirus drug 'major breakthrough'? Coronavirus anti-viral drug 'biggest step forward'? How near are we to curing coronavirus?The double-blind trial involved 101 volunteers who had been admitted for treatment at nine UK hospitals for Covid-19 infections.Half of the participants were given the drug, the other half got what is known as a placebo - an inactive substance.Unconfirme | ![]() amrishbhim | |
20/7/2020 08:50 | I Do hope the II's are puking today! ?? They sold a goldmine for Pennies. | ![]() dovey21 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions